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The technique of gene transfer has been developed over the past decade and enables gene therapy to be applied to patients suffering from inherent metabolic diseases and malignancies. 1, 2 The use of retroviral vectors is the most efficient method of gene therapy and their cDNA usually consists of both a therapeutic and a selection gene such as the neomycin-resistance gene or hygromycin-resistance gene. [3] [4] [5] Using these selection drugs, the retroviral vector-producing cells are selected 10 to 14 days after transduction. Recent investigation has demonstrated the effect of in vivo gene transfer with retroviral vector-producing cells on the treatment of experimental and clinical brain tumors using the herpes simplex virus thymidine kinase (HSVtk) gene, the mechanism of which has been termed the bystander effect. [6] [7] [8] However, it is difficult to introduce retroviral vector-producing cells in vivo for human gene therapy because of the immunological reaction to vector-producing cells by human complement.
It has been reported that the homologous restriction factor 20 (HRF20, CD59) gene, one of the regulators of the complement activation (RCA) molecule, can be used for rapid selection of transduced cells. 9 Due to the transduction of the RCA molecule, xenogeneic cells are resistant to human complement attack. [10] [11] [12] To insert the HRF20 gene, as well as other therapeutic genes into vector-producing cells, the authors established a novel complement-resistant retroviral vector, which possesses the HRF20 gene as a selection gene.
Complement Figure 1 ). To produce virus-producing cells, LRHL retroviral vector was transduced into ⌿2 ecotropic packaging cells, and then the supernatant was poured into PA317 amphotropic packaging cells. After these cells were selected using complement-dependent selection, six colonies were grown. The expression of the HRF20 antigen on these cells was shown to be strongly positive, the mean channel shift of which was 21 ± 5, compared with that of untransduced PA317 cells (1.2 ± 0.3). These six virus-producing cells were used in the transduction experiment.
After NIH3T3 and PK15 cells were transduced with the supernatants from the virus-producing cells, these cells were selected using complement-dependent selection ( Table 1) . As control, those transduced with LRNL retroviral vector were used. A surviving colony after the selection and expression of the HRF20 antigen was observed in the transfectants transduced with complement-resistant retroviral vector, whereas the cells transduced with LRNL control vector did not form a colony after complement-dependent selection.
NIH3T3 and PK15 cells were transduced with LtPARHL retroviral vector to confirm the expression of a second gene using complement-resistant retroviral vector 15 ( Figure 1 ). In this vector, the expression of tPA cDNA was driven by the 5Ј long terminal repeat (LTR). The release of tPA antigen to the culture supernatant from transduced cells was analyzed using ELISA. Hourly tPA secretion was expressed as ng/ml/10 6 cells per hour (Table 2) . After complement-dependent selection, the release of tPA antigen from the cells transduced with LtPARHL retroviral vector was 7.1 ± 1.9 ng/ml/h in NIH3T3 cells and 7.9 ± 2.5 ng/ml/h in PK15 cells, respectively, whereas those with LRHL retroviral vector were below 0.3 ng/ml/h, respectively.
It has been reported that RCA molecules are species- specific and are able to distinguish self from non-self. 16, 17 Recent articles have shown the genetic sequence of DAF (CD55), MCP (CD45) and HRF20 (CD59) as RCA molecules of humans, 512 and CD59 as those of rats and Crry/p65 as those of mice. [18] [19] [20] [21] [22] In this article, the authors demonstrated that the HRF20 antigen was useful as the selection marker of retroviral vector, which rendered the transduced cells resistant to complement-dependent cytolysis. LRHL complement-resistant retroviral vector has a multicloning site (BamHI/SalI) driven by the 5Ј LTR, where another gene can be inserted. Thus the expression of tPA antigen as a second gene has been confirmed using this complement-resistant retroviral vector.
Recent investigations have shown that the in vivo injection of retroviral vector-producing cells has a further effect on cancers and malignant brain tumors compared with that of recombinant retrovirus. However, human organs, except the brain, will not be susceptible to virusproducing cells, since vector-producing cells, such as PA317, are generally derived from murine cells. Thus the establishment of complement-resistant retroviral vector will be feasible for the application of virus-producing cells to malignant diseases in various organs.
It has been reported that RCA molecules such as DAF, MCP and HRF20 regulate the complement activation in human organs, the dysfunction of which correlates with the appearance of congenital disorders and autoimmune diseases such as paroxysmal nocturnal hemoglobinuria and dermatomyositis. [23] [24] [25] On the basis of the findings that RCA molecules have a central role in the inhibition of complement activation, transgenic pigs with human RCA molecules have been created for the clinical application of xenotransplantation. 26, 27 Given the possibility that complement-resistant retroviral vectors render transduced cells both insusceptible to human complement attack and to stable expression of a second gene, this vector will be clinically applicable in the field of human gene therapy and tissue engineering. NIH3T3 and PK15 cells were supplied from ATCC and cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). Rabbit anti-NIH3T3 and PK15 antisera were raised as described in Figure 1 . Target cells were incubated with 1 ml of the supernatant from LRHL retroviral vector in six-well plates containing polybrene for 24 h and cultured with DMEM containing 10% FBS for 3 days. 1 × 10 6 of the cells, selected by complement-dependent selection, were further cultured in six-well plates. Three days after the complementdependent selection, the number of colonies was counted using an occular grid micrometer (Olympus, Tokyo, Japan). After colonies were confluent, 2 × 10 5 of the cells were stained with FITC-1F5 and analyzed using flow cytometry for the expression of HRF20 antigen. As control, NIH3T3 and PK15 cells transduced with LRNL retroviral vector were used. Mann-Whitney U test was performed for the statistical analysis. The number of colony per mm 2 was expressed by mean ± s.d. The expression of HRF20 antigen on transfectants was expressed by mean channel shift (MCS). NIH3T3 and PK15 cells were incubated with 1 ml of the supernatant from LRHL or LtPARHL retroviral vector in six-well plates containing polybrene for 24 h and cultured with DMEM containing 10% FBS for 3 days. 1 × 10 6 cells were selected by complement-dependent selection, and further cultured for 3 days. Six colony-forming cells were picked up and further cultured for confluency in six-well plates. The release of tPA antigen to the culture supernatant from transduced cells was analyzed using ELISA and hourly tPA secretion was expressed as ng/ml/10 6 cells per hour.
